New York approves AI-driven breast cancer diagnostic

New York approves AI-driven breast cancer diagnostic

With Clinical Laboratory Evaluation Program assay validation, the company’s Clinical Laboratory Improvement Amendments-certified lab can begin testing patient samples.WHY IT MATTERS
Along with New York State Department of Health clinical and analytical validation of this use of array morphology, the results of the PDxBr test were reproducible.
“Consistent with our mission of improving healthcare, PDxBr has shown to be an effective prognostic tool to further improve risk stratification over current histopathology methods,” said Wayne Brinster, CEO of PreciseDx, in an announcement.
The company says the AI technology has now proven its ability to enhance invasive breast cancer pathology interpretation with objective, quantifiable and accurate…

Continue Reading